Genmab A/S: Initiation of Coverage- How EPKINLY & Rina-S Are Transforming Cancer Treatment & Investor Sentiment! 

Genmab delivered a mixed first quarter 2025 performance, showcasing notable progress in revenue growth, product approval expansions, and the development of its clinical pipeline while also navigating some challenges. During the first quarter of 2025, Genmab’s revenues increased by 19%, driven predominantly by strong performances from EPKINLY and Tivdak. Both these medicines saw continued market success, with EPKINLY achieving substantial sales growth and expanded approvals across multiple regions including Japan, Europe, and the U.S. EPKINLY’s global sales hit $90 million, highlighting a broad acceptance and positive feedback from physicians for its use in B-cell lymphomas. Tivdak also posted a significant rise in sales, bolstered by establishing itself as a preferred treatment option in recurrent and metastatic cervical cancer.